Electromed Inc (ELMD)vsMerck & Company Inc (MRK)
ELMD
Electromed Inc
$37.69
+2.64%
HEALTHCARE · Cap: $312.08M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 91560% more annual revenue ($65.77B vs $71.75M). ELMD leads profitability with a 14.1% profit margin vs 13.6%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 66/100 (B-).
ELMD
Strong Buy66
out of 100
Grade: B-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.4%
Fair Value
$15.46
Current Price
$37.69
$22.23 premium
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 66.7% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Strong operational efficiency at 20.3%
18.4% revenue growth
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ELMD
The strongest argument for ELMD centers on PEG Ratio, EPS Growth, Altman Z-Score. Revenue growth of 18.4% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ELMD
The primary concerns for ELMD are P/E Ratio, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ELMD profiles as a growth stock while MRK is a value play — different risk/reward profiles.
ELMD carries more volatility with a beta of 0.52 — expect wider price swings.
ELMD is growing revenue faster at 18.4% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ELMD scores higher overall (66/100 vs 50/100) and 18.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Electromed Inc
HEALTHCARE · MEDICAL DEVICES · USA
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?